INTRODUCTION {#sec1-1}
============

Lithium remained the gold standard treatment for patients with bipolar disorders for several decades. During the past six-seven decades, the efficacy and tolerability of lithium in bipolar disorders have been established strongly. It is considered as a first-line drug in acute phases of both mania and depression by the current clinical practice guidelines. Lithium remains the only medication that has been approved by the Food and Drug Administration for maintenance treatment of bipolar disorder. The same was confirmed by the Cochrane collaborative and meta-analyses simultaneously finding equivocal evidence for divalproex and valproic acid as maintenance treatments.\[[@ref1][@ref2][@ref3]\]

Slowly but steadily, the prescriptions of lithium were replaced by the recent psychotropics. This was mainly because of the cumbersome monitoring, adverse effect profile, narrow therapeutic index, and frequent comorbidities in patients, making lithium a second choice drug.\[[@ref4][@ref5]\] Despite psychiatrists being aware of the beneficial effects and monitoring protocols, the place of lithium in their original practice has always been behind. Some studies were done on patients receiving lithium therapy in which they assessed the knowledge and attitude toward treatment using lithium knowledge test. They were done mainly in elderly patients with bipolar disorder.\[[@ref6][@ref7]\] However, the focus on this area had been declining in the recent past and has been shifting toward the understanding of molecular mechanisms of its action and neurotrophic properties.\[[@ref8][@ref9]\] We could not find studies which assessed the knowledge and attitude of psychiatrists toward lithium therapy.

Studies done from India focused on assessing the adverse effects and safety/tolerability profile of lithium,\[[@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] and most of the data are in the form of case reports.\[[@ref16][@ref17][@ref18]\] The issue of pattern of lithium prescription from India is underexplored till now. Hence, we decided to understand the knowledge, attitude, and practice of lithium by a subset of psychiatrists in India, which will help us understand the theory--practice gap and for devising strategies to bridge the existing gap.

MATERIALS AND METHODS {#sec1-2}
=====================

The current study was an online survey which included psychiatrists from India (post-MD/DNB) of either gender and any age group. For the purpose of the study, we have designed a set of 25 questions which had either multiple choice answers or multiple options and some questions based on Likert scale. These questions mainly assessed about the knowledge, attitude, and practice of lithium use among psychiatrists apart from sociodemographic details. This predesigned questionnaire was circulated among the contacts of investigators through E-mail, WhatsApp, Facebook, and other messenger systems. It was done over a period of 1 month (March 2018), and the principal investigators belonged to department of psychiatry, AIIMS Raipur. Only one reminder was sent to all the contacts those who were circulated the survey and anonymity was maintained. Survey was circulated to 424 contacts overall. Respondents could fill the survey through the predesigned questionnaire only once. Among them, we received 135 responses (31% response rate), of which 32 were incomplete. Hence, the total sample of psychiatrists included in the study was 103.

RESULTS OF THE STUDY {#sec1-3}
====================

Sociodemographic distribution {#sec2-1}
-----------------------------

As shown in [Table 1](#T1){ref-type="table"}, the sample which included 103 psychiatrists from India is male predominant, with mean age and duration of experience being 39 years and 12.5 years, respectively. Most of them worked in urban area and more or less equally distributed among institution based, private setup, and both the sectors.

###### 

Sociodemographic distribution

  Variable             Frequency (%)/mean (SD)
  -------------------- -------------------------
  Age (years)          39.7 (10.8)
  Gender               
   Male                86 (83.5)
   Female              17 (16.5)
  Current work         
   Institution based   40 (38.8)
   Private practice    36 (35)
   Both                27 (26.2)
  Place of work        
   Rural               5 (4.9)
   Semiurban           25 (24.3)
   Urban               73 (70.9)
  Experience (years)   12.5 (10.31)

SD -- Standard deviation

Knowledge about lithium use {#sec2-2}
---------------------------

When the knowledge about stabilization of lithium doses in acute stage and prophylaxis was assessed, almost 75% of the respondents did that on a dose-dependent basis rather than blood level dependent (25%). More than 60% of those who preferred dose-dependent titration opined that patients in acute stage needed doses more than 900 mg whereas same proportion of them opined that most patients need doses \<900 mg in their maintenance stage.

About 12% of the psychiatrists from the sample preferred to use lithium once daily compared to multiple times a day (88%), irrespective of the phase of bipolar disorder \[[Table 2a](#T2a){ref-type="table"}\].

###### 

Dosing in acute stage and maintenance

  Variable                                                      Frequency (%)
  ------------------------------------------------------------- ---------------
  Acute                                                         
   Dose dependent                                               78 (75.7)
   \<900 mg                                                     29 (37)
   \>900 mg                                                     49 (63)
   Blood level dependent                                        25 (24.3)
  Maintenance                                                   
   Dose dependent                                               77 (74.8)
   \<900                                                        64
   \>900                                                        13
   Blood level dependent                                        26 (24.2)
  Frequency of monitoring lithium levels in maintenance phase   
   3 monthly                                                    42 (40.8)
   6 monthly                                                    46 (44.7)
   1 monthly                                                    4 (3.9)
   Yearly                                                       6 (5.8)
   Based on feasibility                                         5 (4.9)
  Dosing frequency                                              
   Once daily                                                   12 (11.7)
  \>Once daily                                                  91 (88.3)

Nearly, 96% of the psychiatrists were of the opinion that at least lithium was moderately effective in lowering the suicidal risk due to any cause \[[Table 2b](#T2b){ref-type="table"}\].

###### 

Perceived effectiveness of lithium in lowering the suicidal risk

  Variable                             Frequency (%)
  ------------------------------------ ---------------
  Don't use lithium for that purpose   2 (1.9)
  Ineffective                          2 (1.9)
  Moderate effective                   40 (38.8)
  Somehow effective                    14 (13.6)
  Very effective                       45 (43.7)

Attitude about using lithium {#sec2-3}
----------------------------

When asked about their level of comfort in using lithium on an outpatient basis, around 70% of them opined that they are very comfortable in using lithium.

In case of using lithium as an augmenting agent for treatment-resistant depression, around 50% of the psychiatrists were very comfortable in prescribing lithium for that purpose \[[Figure 1](#F1){ref-type="fig"}\].

![Perceived level of comfort in using lithium](IJPsy-61-451-g001){#F1}

Most of the psychiatrists preferred using lithium in patients aged between 20 and 39 years (94%) which was followed by 40--64 age group who constituted up to 59% whereas psychiatrists were not comfortable in using lithium in elderly (3%) and in adolescents (17%).

Practice of lithium prescription {#sec2-4}
--------------------------------

When asked about the option of preferred agent as followed in their actual clinical practice, following were the responses received \[[Figure 2](#F2){ref-type="fig"}\].

![Preferred treating agent in clinical practice](IJPsy-61-451-g002){#F2}

In a patient presenting with acute mania and past history of bipolar disorder, 60% of them preferred starting lithium compared to valproate and other mood stabilizers (40%). In first episode mania patients, valproate (40%) was preferred as a first choice followed by lithium (35%) and antipsychotics (20%). Lithium was the first choice as augmenting agent in treatment-resistant depression followed by antipsychotics, another antidepressant, and thyroid supplementation, respectively.

Lithium was used more frequently in both first episode and multiepisode mania by psychiatrists with duration of experience more than 5 years. Furthermore, psychiatrist with higher duration of experience used lithium more frequently in cases of mild cognitive impairment \[[Table 2c](#T2c){ref-type="table"}\].

###### 

Relation of lithium use and duration of experience

  Variable                                       Experience (%)   *χ*^2^ (*P*)   
  ---------------------------------------------- ---------------- -------------- ------------------
  Drug commonly used in first episode mania                                      
   Lithium                                       9 (8.8)          26 (25)        104.32 (\<0.001)
   Others                                        21 (20.3)        47 (45.6)      
  Drug commonly used in multiepisode mania                                       
   Lithium                                       20 (19.4)        40 (38.8)      105.22 (\<0.001)
   Others                                        10 (9)           33 (32.0)      
  Use of lithium for mild cognitive impairment                                   
   Yes                                           16 (15.5)        30 (29.1)      105.30
   No                                            14 (13.5)        43 (41.7)      (\<0.001)

The most common obstacle as perceived by psychiatrists in prescribing lithium was patient\'s clinical comorbidities followed by low adherence rate to serum level monitoring. Other frequent reasons preventing starting of lithium were burden of adverse effect monitoring and slow action of lithium \[[Table 2d](#T2d){ref-type="table"}\].

###### 

Obstacles perceived by psychiatrists in prescribing lithium

  Obstacles in prescribing lithium                    Frequency (%)
  --------------------------------------------------- ---------------
  Adverse effect monitoring                           19 (18.4)
  Difficulty in dose titration                        2 (1.9)
  Lack of experience                                  3 (2.9)
  Patient's clinical comorbidities                    33 (32.0)
  Patient's low adherence to serum-level monitoring   30 (29.1)
  Slow action of lithium                              16 (15.5)

As a part of prelithium workup \[[Table 2e](#T2e){ref-type="table"}\], more than half of the sample preferred in investigating renal function tests (93%), thyroid function tests (91%), electrocardiography (58%), and weight monitoring (56%) while estimated glomerular filtration rate (25%) is the least preferred among all. When asked about management of polyuria associated with lithium, 43.7% of respondents said that they would reassure the patient first, which was followed by discontinuing lithium (31.1%) and starting thiazide diuretics (11.7%). Regarding hypothyroidism associated with lithium, 75.7% of psychiatrists preferred to continue lithium by adding thyroxine, 31.1% preferred to add thyroxine but to discontinue lithium whereas 22.3% preferred to change mood stabilizer. Following lithium toxicity, a third of psychiatrists preferred not to rechallenge, one-third of them wanted to rechallenge, whereas one-third were not sure about the same.

###### 

Prelithium workup and management strategies for adverse effects of lithium

  Variable                                                   Frequency (%)
  ---------------------------------------------------------- ---------------
  Prelithium workup (multiple responses permitted)           
   Thyroid function tests                                    94 (91)
   Renal function tests                                      96 (93)
   eGFR                                                      26 (25)
   ECG                                                       60 (58)
   Weight                                                    58 (56)
  How do you manage polyuria associated with lithium         
   Reassurance                                               45 (43.7)
   Discontinue lithium                                       32 (31.1)
   Start thiazides                                           12 (11.7)
   Others                                                    14 (13.6)
  How do you manage hypothyroidism associated with lithium   
   Add thyroxine and continue lithium                        78 (75.7)
   Add thyroxine and discontinue lithium                     32 (31.1)
   Discontinue lithium and change mood stabilizer            23 (22.3)
  Would you rechallenge following lithium toxicity           
   May be                                                    40 (38.8)
   Yes                                                       32 (31.1)
   No                                                        31 (30.1)

ECG -- Electrocardiography; eGFR -- Estimated glomerular filtration rate

DISCUSSION {#sec1-4}
==========

In this study, we attempted to assess the knowledge, attitude, and practices of lithium therapy among psychiatrists in India. This way, we tried to indirectly assess the factors responsible for theory--practice gap for the prescription of lithium in bipolar disorders.

The current study unfolded several important practical difficulties in using lithium in various settings. The majority of psychiatrists who completed the survey were of the opinion that lithium dosing should be done both in the acute phase and maintenance phase on a dose-dependent basis rather than the blood level-dependent basis. Despite the evidence-based recommendations\[[@ref5][@ref19][@ref20]\] by guidelines that dose adjustment of lithium should be done on the basis of serum lithium levels irrespective of the phase of the illness, this contrary finding of ours suggests that the busy schedules, hectic outpatient clinics, cost factor, and poor adherence to blood monitoring by the patients might be contributory to this view.

Majority of the psychiatrists were of the view that lithium is useful in patients with suicidal risk/attempts, treatment-resistant depression, and bipolar mania. Their views were in line with the current existing evidence for the abovementioned indications.\[[@ref21][@ref22][@ref23]\] Despite this, they were skeptical in starting lithium in such patients due to multitude of barriers such as comorbidities, patient\'s low adherence to blood monitoring, and adverse effects. These could be the reasons behind psychiatrists preferring valproate to lithium in first episode mania.

A review done to understand the safety and tolerability profile of lithium in bipolar disorder patients clearly replicates the fact that there are definite adverse effects due to the drug. However, the proportion of those who do not develop them is higher than the ones who develop and most of them can be avoided or managed by simple strategies if one is aware about them.\[[@ref24][@ref25]\] For example, once-daily dosing and keeping lithium levels low prevent the development of renal impairment in a multitude of patients.\[[@ref26][@ref27]\] However, in our study, psychiatrists preferred using multiple dosing to once-daily dose, suggesting theory--practice gap in the prescription patterns.

Bipolar treatment guidelines suggest that side effects such as hypothyroidism (both overt and subclinical) can be easily treated with thyroxine supplementation and our study finding represented the same. The dilemma in this regard is whether the patient developed hypothyroid state due to the preexisting mood disorder itself or the drug exerts an independent effect on the person. Furthermore, evidence about the teratogenicity of lithium is not confirmatory. Although we cannot rule out the teratogenic nature of the drug, the risk has been definitely overestimated. Furthermore, one has to bear in mind the fact that the newer drugs which are being used widely in place of lithium are not devoid of adverse effects although their profile of side effects is different from that of lithium.\[[@ref28][@ref29]\]

Limitations {#sec2-5}
-----------

Our study has certain limitations; the small sample of psychiatrists included in the study and the relatively poor response rate might not exactly depict the situations. It is not representative of psychiatrists from all over India. Furthermore, there might be a discrepancy between the responses given and the actual practice. It might be due to the hectic outpatient clinics, bothersome monitoring of adverse effects, and the fall in popularity of the lithium due to promotion of newer drugs by pharmaceutical companies. As it was an online survey, it might not have included the experienced psychiatrists who were using lithium in their actual practice more than the current generation ones, which is reflected on by the mean age of 39 years. The options that were given for the questions might be limited as we have used a semistructured questionnaire for assessment rather than a validated scale.

CONCLUSIONS AND FUTURE DIRECTIONS {#sec1-5}
=================================

In conclusion, our study found certain factors which might be a hindrance for the use of lithium in clinical settings. Duration of experience as a psychiatrist was the factor which affected the higher use of lithium in indicated conditions. Most psychiatrists in the survey preferred using lithium multiple times a day and on a dose-dependent basis contrary to the guidelines. And also, we found that although the participants were aware of the indications and monitoring techniques, they perceived certain obstacles while actually using lithium in their clinical practice. Therefore, improving the knowledge of psychiatrists about the incidence of adverse effects and techniques of managing the side effects can reduce their reluctance in starting lithium therapy.

Contrary to the usual notion, psychiatrists should understand that the side effects of lithium are not as malignant as presumed to be, particularly at therapeutic doses. Side effects such as tremors can be easily managed by reducing dose to below one\'s side effect threshold, as clinical effects can be seen at lower levels or with β-blockers. Lithium-induced hypothyroidism can be easily corrected by addition of thyroid supplementation, and use of minimum effective doses with monitoring can reduce the renal damage due to lithium. Despite its side effects, it is one of the few drugs which has been approved for the treatment of suicidality.\[[@ref30]\]

Particularly, the young psychiatrists should receive necessary training in starting and monitoring patients on lithium therapy.\[[@ref1]\] There is a need to emphasize to physicians about the cost-effectiveness of lithium therapy. This should be achieved through education programs and workshops. This will help them to use lithium in a more appropriate manner in their clinical practice. That way, we can save the "magic molecule" from its downfall, utilizing it for the needy. Also, the recent evidence from preclinical studies that documented the neuroprotective effects of lithium both by preventing apoptosis and promoting neurogenesis has suggested the potential benefits of using it in the management of neurodegenerative diseases, neurodevelopmental disorders, and hypoxic-ischemic/traumatic brain injury.\[[@ref31][@ref32][@ref33]\] Further studies should be conducted on a large scale to explore the usefulness of lithium and to help psychiatrists get over the barriers.
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